Stocktoria
Twist Bioscience Corp TWST
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2018-10-31
Twist Bioscience Corp statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -36.2% | -70.6% | -88.6% | -115.3% | -115.4% |
| Net margin | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% |
| FCF margin | -20.1% | -22.1% | -69.5% | -111.1% | -105.3% |
| Return on assets | -12.1% | -34.0% | -26.4% | -22.7% | -21.7% |
| Return on equity | -16.4% | -44.2% | -32.8% | -27.6% | -26.2% |
| Current ratio | 3.64 | 4.88 | 5.79 | 6.58 | 8.67 |
| Revenue growth | 20.3% | 27.7% | 20.4% | 53.8% | 46.9% |
Source: SEC EDGAR filings · CIK 0001581280 · as of 2025-09-30. Facts from filings plus Stocktoria's own computed scores — not investment advice.